Puma Biotechnology

229 articles with Puma Biotechnology

• Puma Biotechnology’s Licensing Partner Specialised Therapeutics Asia Receives Regulatory Approval to Commercialize NERLYNX® (neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer

  3/18/2019

  Neratinib becomes the first anti-HER2 treatment to be approved in Australia, as extended adjuvant therapy for early stage HER2-positive breast cancer following adjuvant trastuzumab-based therapy.

• Puma Biotechnology Presents Interim Results from the Phase II SUMMIT Trial of Neratinib for HER2 (ERBB2) Mutant, Metastatic Cervical Cancer at the Society of Gynecologic Oncology (SGO) 2019 Annual Meeting

  3/18/2019

  Puma Biotechnology, Inc. an ongoing Phase II basket trial examining the efficacy of neratinib in HER2-mutated cancers, were reported at the Society of Gynecologic Oncology (SGO) 2019 Annual Meeting in Honolulu, Hawaii.

• Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - March 14, 2019

  3/14/2019

  Puma Biotechnology, Inc., a biopharmaceutical company, announced that on March 12, 2019 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 30,688 shares of Puma common stock to five new non-executive employees.

• Puma Biotechnology to Present at Cowen’s Annual Health Care Conference

  3/5/2019

  Puma Biotechnology, Inc., a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 10:00 a.m. EDT on Tuesday, March 12 at the Cowen and Company 39th Annual Health Care Conference.

• Puma Biotechnology Reports Fourth Quarter and Full Year 2018 Financial Results

  2/28/2019

  Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2018

• Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

  2/15/2019

  Puma Biotechnology, Inc. announced that on February 14, 2019 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 16,375 shares of Puma common stock to three new non-executive employees.

• Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results on Thursday, February 28, 2019

  2/13/2019

  Puma Biotechnology, Inc., a biopharmaceutical company, will host a conference call at 1:30 p.m. PST/4:30 p.m. EST on Thursday, February 28, 2019 following release of its fourth quarter and full year 2018 financial results.

• Puma Biotechnology Announces Litigation Victory with Jury’s Decision

  2/5/2019

  Puma Biotechnology, Inc. announced that the class action lawsuit, Hsu vs. Puma Biotechnology, Inc., et. al., filed in the U.S. District Court for the Central District of California against Puma and Alan H. Auerbach, Puma’s CEO and President, has concluded with a jury verdict.

• Puma Biotechnology and Knight Therapeutics Enter into Exclusive License Agreement to Commercialize NERLYNX® (neratinib) in Canada

  1/11/2019

  Puma Biotechnology, Inc. announced that it has entered into an exclusive License Agreement with Knight Therapeutics Inc. (TSX: GUD) that grants Knight the exclusive right to commercialize NERLYNX® (neratinib) in Canada.

• Puma Biotechnology to Present at J. P. Morgan Healthcare Conference

  1/3/2019

  Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 12:00 Noon PST on Wednesday, January 9,

• Puma Biotechnology Reports on December 30, 2018 Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

  1/2/2019

  Puma Biotechnology, Inc. announced that on December 30, 2018 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 10,750 shares of Puma common stock to three new non-executive employees.

• Puma Biotechnology Announces Top Line Results of the Phase III NALA Trial of Neratinib in Patients with HER2-Positive Metastatic Breast Cancer

  12/17/2018

  Bristol-Myers Squibb Company (NYSE:BMY), and Boston Medical Center, a private, not-for-profit, academic medical center, today announced a multi-year joint research study to identify and analyze potential sensitivity and resistance markers in patients treated with standard-of-care checkpoint inhibitors.

• Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) on December 11, 2018

  12/11/2018

  Puma Biotechnology, Inc. announced that in connection with the appointment of Maximo F. Nougues as Puma’s Chief Financial Officer, the Compensation Committee of Puma’s Board of Directors approved a grant to Mr. Nougues of an inducement stock option to purchase 90,000 shares of Puma common stock, at an exercise price per share equal to the closing price of Puma’s common stock on the grant date.

• Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) on December 10, 2018

  12/10/2018

  Puma Biotechnology, Inc. announced that in connection with the appointment of Maximo F. Nougues as Puma’s Chief Financial Officer, the Compensation Committee of Puma’s Board of Directors approved a grant to Mr. Nougues of an inducement stock option to purchase 90,000 shares of Puma common stock, at an exercise price per share equal to the closing price of Puma’s common stock on the grant date.

• Puma Biotechnology Presents Results from the Hormone Receptor Positive Subgroup in Phase III ExteNET Trial of Neratinib for HER2-Amplified, Early Stage Breast Cancer at the 2018 San Antonio Breast Cancer Symposium

  12/6/2018

  Puma Biotechnology, Inc. announced that results from the subgroup of patients with hormone receptor positive (HR-positive) breast cancer from the Company’s Phase III ExteNET Trial of neratinib for early stage HER2-Amplified breast cancer are being presented at the 2018 San Antonio Breast Cancer Symposium (SABCS) that is currently taking place in San Antonio, Texas.

• Puma Biotechnology Presents Results of Patient Reported Outcomes in Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2018 San Antonio Breast Cancer Symposium

  12/6/2018

  Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, is presenting updated results from a Phase II clinical trial of Puma’s drug neratinib at the 2018 San Antonio Breast Cancer Symposium (SABCS) that is currently taking place in San Antonio, Texas.

• Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2018 San Antonio Breast Cancer Symposium

  12/6/2018

  Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that results from an ongoing Phase II clinical trial of Puma's drug neratinib are being presented at the 2018 San Antonio Breast Cancer Symposium (SABCS) that is currently taking place in San Antonio, Texas

• uBiome Announces First Stage of CDx Development in Collaboration w/ Puma Biotechnology

  12/5/2018

  Today announced the first stage of companion diagnostic development with Puma Biotechnology to investigate the role of the microbiome in adverse events related to neratinib treatment of patients with HER2-positive breast cancer. 

• Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) on December 2, 2018

  12/3/2018

  Puma Biotechnology, Inc. announced that on December 2, 2018 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 44,875 shares of Puma common stock to 10 new non-executive employees.

• 

  Drug Approvals for the 2 Most Common Types of Cancer in the Last 2 Years

  11/19/2018

  According to the American Cancer Society, almost 601,000 people in the U.S. died of cancer in 2017. The two most common types of cancer are lung cancer and breast cancer, followed by colorectal cancer, prostate cancer and stomach cancer.